[ad_1] Eisai has agreed a deal to settle patent infringement litigation with generic drugmaker Torrent Pharma, preventing it from launching a copycat version of Eisai’s MSD-partnered cancer drug Lenvima in the US until 2030. The deal sets aside litigation being heard in a New Jersey district court, which alleged that Torrent’s marketing application for a…
[ad_1] Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer’s disease therapy. The green light for Leqembi Iqlik (lecanemab) means it can be used as an alternative to infusions during the maintenance phase of treatment with the anti-amyloid therapy, and patients will…
[ad_1] Biogen, Eisai get USFDA nod for Leqembi Iqlik Subcutaneous Injection for maintenance dosing for early Alzheimer’s Disease We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen’s much-delayed drug for early-stage Alzheimer’s disease. Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday (1st September), becoming the first drug in the class to…